# MUTATE: A Human Genetic Atlas of Multi-organ AI Endophenotypes using GWAS Summary Statistics

3

4 Junhao Wen<sup>1\*</sup>, Christos Davatzikos<sup>2</sup>, Jian Zeng<sup>3</sup>, Li Shen<sup>4</sup>, Andrew Zalesky<sup>5</sup>, Ye Ella Tian<sup>5</sup>,

- 5 Zhijian Yang<sup>2</sup>, Aleix Boquet-Pujadas<sup>7</sup>
- 5 6 7 8 9

<sup>1</sup>Laboratory of AI and Biomedical Science (LABS), University of Southern California, Los Angeles, California,
 USA

- 9 <sup>2</sup>Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated
- 10 Diagnostics (AI<sup>2</sup>D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

<sup>3</sup>Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia

- <sup>4</sup>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
- <sup>5</sup>Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of
- 15 Melbourne, Melbourne, Victoria, Australia
- 16 <sup>6</sup>Biomedical Imaging Group, EPFL, Lausanne, Switzerland
- 17


- 19 Junhao Wen, junhaowe@usc.edu
- 20 2025 Zonal Ave, Los Angeles, CA 90033, United States
- 21

<sup>18 \*</sup>Corresponding authors:

# 22 Highlight

- Two AI- and neuroimaging-derived subtypes of schizophrenia (SCZ1 and SCZ2) show
   lower polygenicity and weaker negative selection signatures than the disease
   endpoint/diagnosis of schizophrenia, supporting the endophenotype hypothesis.
- Brain AI endophenotypes are more polygenic than other organ systems.
- Most multi-organ AI endophenotypes exhibit negative selection signatures, whereas a
   small proportion of brain patterns of structural covariance networks exhibit positive
   selection signatures.
- The 2024 multi-organ AI endophenotypes are genetically and causally associated with
   within-organ and cross-organ disease endpoints/diagnoses.

# 32 Graphical abstract



33

# 34 Keywords

35 Multi-organ AI endophenotypes, genetic correlation, Mendelian randomization, polygenic risk

36 score

37

#### 38 Summary

- 39 Artificial intelligence (AI) has been increasingly integrated into imaging genetics to provide
- 40 intermediate phenotypes (i.e., endophenotypes) that bridge the genetics and clinical
- 41 manifestations of human disease. However, the genetic architecture of these AI endophenotypes
- 42 remains largely unexplored in the context of human multi-organ system diseases. Using publicly
- 43 available GWAS summary statistics from UK Biobank, FinnGen, and the Psychiatric Genomics
- 44 Consortium, we comprehensively depicted the genetic architecture of 2024 multi-organ AI
- 45 endophenotypes (MAEs). Two AI- and imaging-derived subtypes<sup>1</sup> showed lower polygenicity
- 46 and weaker negative selection effects than schizophrenia disease diagnoses<sup>2</sup>, supporting the
- 47 endophenotype hypothesis<sup>3</sup>. Genetic correlation and Mendelian randomization results
- 48 demonstrate both within-organ connections and cross-organ talk. Bi-directional causal
- 49 relationships were established between chronic human diseases and MAEs across multiple organ
- 50 systems, including Alzheimer's disease for the brain, diabetes for the metabolic system, asthma
- 51 for the pulmonary system, and hypertension for the cardiovascular system. Finally, we derived
- 52 the polygenic risk scores of the 2024 MAEs. Our findings underscore the promise of the MAEs
- as new instruments to ameliorate overall human health. All results are encapsulated into the
- 54 MUTATE genetic atlas and are publicly available at https://labs-laboratory.com/mutate.

### 55 Introduction

Multi-organ research<sup>1,4–11</sup> represents a pivotal frontier in advancing our understanding of human aging and disease. In particular, integrating artificial intelligence (AI) into multi-organ imaging genetics<sup>1,4,12,6</sup> has emerged as a novel approach, offering potential promise in advancing precision medicine<sup>13</sup>. This integration introduces a new array of endophenotypes<sup>14,15</sup>, serving as intermediate, often quantitative, phenotypes, potentially reshaping how we perceive and approach medical AI<sup>16</sup> in imaging and genetic research.

In recent years, three primary catalysts have significantly advanced the field of genetics. 62 63 The first pivotal factor stems from the extensive collaborative efforts in consolidating large-scale multi-omics datasets, which has endowed researchers with unprecedented statistical power 64 previously inaccessible. As an illustration, the UK Biobank (UKBB) study<sup>17</sup> stands out for its 65 comprehensive collection of multi-organ imaging<sup>18</sup>, genetics<sup>19</sup>, and proteomics<sup>20,21</sup> data within the United Kingdom. Similarly, the FinnGen study<sup>22</sup>, conducted in Finland, has amassed 66 67 extensive clinical and genetic data. Secondly, efforts toward open science have propelled the 68 field, especially emphasizing the significance of publicly available resources, such as genome-69 70 wide association study (GWAS) summary statistics and widespread scientific dissemination. Notably, the FinnGen study and Psychiatric Genomics Consortium (PGC<sup>23</sup>) have publicly made 71 all the GWAS summary statistics accessible<sup>22</sup>. Public GWAS platforms such as the GWAS 72 Catalog<sup>24</sup>, OpenGWAS<sup>25</sup>, and GWAS ATLAS<sup>26</sup> have consolidated and harmonized vast GWAS 73 74 datasets, rendering them suitable for subsequent genetic analyses. Likewise, such good practice was also employed in the newly burgeoning field of brain imaging genetics<sup>27</sup>, including the 75 76 BIG40 (https://open.win.ox.ac.uk/ukbiobank/big40/), the BIG-KP (https://bigkp.org/), 77 BRIDGEPORT (https://labs-laboratory.com/bridgeport), and MEDICINE (https://labs-78 laboratory.com/medicine) knowledge portals. Finally, advanced computational genomics 79 statistical methods using solely GWAS summary statistics, along with sufficient linkage 80 disequilibrium information, have been developed, presenting an unparalleled chance to comprehend the genetic architecture of highly polygenic disease traits. For example,  $LDSC^{28}$  has 81 82 been extensively utilized to estimate single-nucleotide polymorphism (SNP)-based heritability and genetic correlations. Mendelian randomization<sup>29</sup> is a statistical method to dissect associations 83

further, probing potential causal relationships among these complex human disease traits,
 although these methods often rely on several sensitive model assumptions<sup>30</sup>.

86 Despite these advancements, the intricate genetic foundation shaping these AI 87 endophenotypes in the context of pleiotropic human disease endpoints (DE) within multi-organ 88 systems remains largely uncharted. We previously applied AI to imaging genetic data and 89 derived 2024 multi-organ AI endophenotypes (MAE). These encompassed 2003 multi-scale 90 brain patterns of structural covariance (PSC) networks generated through a deep learninganalogy non-negative matrix factorization method<sup>12</sup> (visualization for C32\_1 encompassing deep 91 92 subcortical structures: https://labs-laboratory.com/bridgeport/MuSIC/C32 1), 9 dimensional neuroimaging endophenotypes (DNE) quantifying neuroanatomical heterogeneity (also known as 93 94 disease subtype) within 4 common brain diseases<sup>1</sup>, and 12 biological age gap (BAG) assessing 95 the individual deviation in typical aging (i.e., acceleration or deceleration from the chronological age) across 9 human organ systems<sup>4,6</sup> (Supplementary eTable 1a). To contribute to open 96 97 science<sup>31</sup>, we made all the GWAS summary statistics derived from UKBB data publicly 98 available at the MEDICINE knowledge portal: https://labs-laboratory.com/medicine. In addition, 99 FinnGen analyzed genetic data for 2269 binary and 3 quantitative DEs from 377,277 individuals

and 20,175,454 variants. They made these massive GWAS summary statistics publicly available

- 101 to the community at <a href="https://finngen.gitbook.io/documentation/">https://finngen.gitbook.io/documentation/</a> (Supplementary eTable 1b).
- 102 Finally, PGC consolidated GWAS results focused on neurological disorders worldwide and
- 103 made the GWAS summary statistics accessible to the research community (<u>https://pgc.unc.edu/</u>,
- 104 **Supplementary eTable 1c**).
- 105 This study harnesses the extensive GWAS summary resources made publicly available
- 106 by us on behalf of UKBB, FinnGen, and PGC (**Method 1**), along with the utilization of several
- 107 advanced computational genomics statistical methods (refer to Code Availability), to thoroughly
- 108 depict the genetic architecture of the 2024 MAEs (Method 2) and 525 DEs (>5000 cases) in the
- 109 context of multi-organ investigations. Importantly, our previous research explored the genetic
- 110 foundation of the 2024 MAEs but did not systematically encompass the FinnGen or PGC data.
- 111 Specifically, we included 521 DEs released by the FinnGen study, accessible at
- 112 <u>https://finngen.gitbook.io/documentation/v/r9/</u>, and 4 brain DEs (Alzheimer's disease (AD),
- 113 Attention-deficit/hyperactivity disorder (ADHD), bipolar disorder (BIP), and schizophrenia
- 114 (SCZ)) from PGC (<u>https://pgc.unc.edu/</u>). This study expanded on this by systematically
- 115 benchmarking the genetic analyses and comprehensively comparing various statistical
- 116 methodologies  $^{28,30,32-38}$  (Method 3). Specifically, we aimed to compute the SNP-based
- heritability  $(h_{SNP}^2)$ , polygenicity  $(\pi)$ , the relationship between SNP effect size and minor allele
- frequency (S: signature of natural selection, genetic correlation ( $r_a$ ), causality, and polygenic risk
- score (PRS) between the 2024 MAEs and 525 DEs. These findings were encapsulated within the
- 120 MUTATE (**MU**ITi-organ **A**I endopheno**T**yp**E**) genetic atlas, which is publicly available at
- 121 <u>https://labs-laboratory.com/mutate</u>.

#### **Results** 122


#### 123 The genetic architecture of the 2024 MAEs and 525 DEs

- 124 We computed three parameters to fully depict the genetic architecture of the 2024 MAEs
- (Method 3a). For the SNP-based heritability  $(h_{SNP}^2)$ , SBayesS<sup>39</sup> obtained the highest  $h_{SNP}^2$  for the 125
- 2016 brain MAEs (mean  $\hat{h}_{SNP}^2$ =0.13 [0.01, 0.38]), followed by the pulmonary BAG 126
- $(0.16\pm0.004)$ , the eye BAG  $(0.14\pm0.009)$ , the cardiovascular BAG  $(0.12\pm0.003)$ , the renal BAG 127
- 128 (0.10±0.003), and the musculoskeletal BAG (0.10±0.003) (Fig. 1a and Supplementary eFile 1).
- It is worth noting that SNP-based heritability varies across methods and depends on the input 129
- 130 data, i.e., summary data or individual-level genotype data used in the method<sup>40</sup>. We aimed to
- benchmark the summary data-based methods by comparing the results from SBayesS with those 131
- of LDSC<sup>28</sup> and SumHer<sup>33</sup>. Overall, while the estimates from the three methods were highly 132 correlated (r=0.97 between LDSC and SumHer; r=0.99 between SBayesS and SumHer; r=0.99
- 133 134
- between SBayesS and LDSC; Supplementary eFigure 1), SumHer (0.23±0.14) generally
- 135 yielded larger  $h_{SNP}^2$  estimates than both LDSC (0.16±0.10) and SBayesS (0.13±0.08)
- (Supplementary eFile 1). We present the  $h_{SNP}^2$  estimate of the 525 DEs and 2024 MAEs in 136
- Supplementary eFigure 2. Supplementary eFile 2 presents the results of the 525 DEs. For the 137
- 525 DEs, we converted the  $h_{SNP}^2$  estimates from the observed scales to the liability scales, following the recommendations of Ojavee et al<sup>41</sup>. It's important to clarify that we did not intend 138
- 139 to compare the  $h_{SNP}^2$  estimates of the two data sources due to differences in genotype coverage, 140
- 141 sample sizes, allele frequencies, and other factors.
- We then computed the natural selection signature (S) for the 2024 MAEs. The metabolic 142
- BAG showed a strong negative selection ( $S=-0.82\pm0.10$ ), followed by the pulmonary BAG ( $S=-0.82\pm0.10$ ) 143
- 144  $0.79\pm0.05$ ), the hepatic BAG (S=-0.74±0.09), the renal BAG (S=-0.68±0.08), and the immune
- 145 BAG (S=-0.66±0.11). For the brain MAEs (S=-0.33 [-1, 0.43]), the brain BAG and (S=-
- $0.70\pm0.12$ ) the subtype (ASD1) for autism spectrum disorder<sup>42</sup> (S=-0.90\pm0.11) showed strong 146
- negative selection effects (Fig. 1b and Supplementary eFile 3). 147
- 148 Finally, we calculated the polygenicity  $(\pi)$  for the 2024 MAEs. We found that brain
- 149 MAEs (0.040 [0.003, 0.072]) showed higher polygenicity than other organ systems, followed by
- 150 the pulmonary BAG ( $0.018\pm0.001$ ), the musculoskeletal BAG ( $0.013\pm0.001$ ), and the
- 151 cardiovascular BAG (0.011±0.001) (Fig. 1C and Supplementary eFile 4). The PSC (C128\_115:
- 152 https://labs-laboratory.com/bridgeport/MuSIC/C128\_115) showed the highest polygenicity 153 estimate (0.072±0.002).
- 154

#### 155 Supporting evidence for the endophenotype hypothesis

- Previous studies<sup>43,44</sup> have found supporting evidence for the endophenotype hypothesis<sup>14,15</sup> using 156
- traditional brain map-based signatures, showing that more genes are associated with disease 157
- 158 endpoints than imaging-derived signatures (i.e., endophenotypes). Of note, considering genetic
- 159 differences between FinnGen and UKBB samples, SBayesS with the UKBB as LD reference
- 160 may give biased estimates of S and  $\pi$  (LD from FinnGen not fully available: **Method 3a**).
- 161 Therefore, we used the GWAS summary data for PGC schizophrenia ( $SCZ^2$ ) and two subtypes
- of SCZ (SCZ1 and SCZ2<sup>1</sup>) from our UKBB analysis to demonstrate this. The advantage of using 162
- 163 PGC data is that the GWAS summary statistics are better powered (large sample sizes), and the
- 164 data were from European ancestry groups across different countries. A data harmonization
- 165 procedure is outlined in **Supplementary eMethod 1** to ensure a fair comparison of these
- 166 estimates, which led to the utilization of a common set of SNPs and linkage disequilibrium

- 167 information for computing the *S* and parameters. Our results showed that SCZ1
- 168 ( =0.048 $\pm$ 0.002; S=-0.61 $\pm$ 0.09) and SCZ2 ( =0.047 $\pm$ 0.002; S=-0.54 $\pm$ 0.12) had lower
- 169 polygenicity signals and weaker negative selection effects than SZC ( $=0.055\pm0.003$ ; S=-
- 170 0.82±0.04) (Fig. 1d). Supplementary eFigure 3 shows the Manhattan plot of the harmonized
- summary data for SCZ1, SCZ2, and SCZ. These findings support the endophenotype
- 172 hypothesis<sup>3</sup>, which suggests that intermediate phenotypes (such as SCZ subtype MAEs) are part
- 173 of the causal pathway from genetics to exo-phenotypes (such as SCZ binary diagnosis), making
- 174 them closer to the underlying etiology. Consequently, the SCZ subtypes were found to be less
- 175 polygenic<sup>43,44</sup>



176

#### 177 Figure 1: The genetic architecture of the 2024 MAEs


- 178 Three parameters are estimated by SBayesS to delineate the genetic architecture of the 2024
- 179 MAEs, including (a) the SNP-based heritability ( ), (b) the relationship between MAF and
- 180 effect size (S), and (c) polygenicity (). (d) We compared the and S parameters using
- harmonized GWAS summary data for two AI- and imaging-derived subtypes (SCZ1 and SCZ2<sup>1</sup>)
- 182 from UKBB and the disease endpoint of schizophrenia (SCZ<sup>2</sup>) from PGC. FinnGen data was not
- used due to bias stemming from the unavailability of FinnGen-specific linkage disequilibrium
- data (Supplementary eMethod 1). We present the distribution of the estimated parameters for
   the 2016 brain MAEs using a violin plot; the mean value is denoted by the black horizontal line.
- 185 the 2010 b.

### 187 The genetic correlation shows organ-specific and cross-organ associations


- 188 We found 132 (P-value < 0.05/2024) and 45 (P-value < 0.05/2024/525) commonly significant
- positive genetic correlations  $(r_g)$  after applying two levels of Bonferroni correction (Fig. 2) for
- 190 the LDSC<sup>28</sup> and GNOVA<sup>34</sup> methods (Method 3b, Supplementary eFile 5, and Supplementary

eTable 2). We noted that HDL encountered convergence issues with the models, as detailed in
Method 3b.

- Between these methods, the magnitude of the genetic correlations for the significant signals for both methods differed: mean  $\hat{r}_g$ =0.24[-0.40~0.52] with 213 significant signals for LDSC, mean  $\hat{r}_g$ =0.17[-0.30~0.62] for GNOVA with 428 significant signals (**Fig. 2**). The three sets of converged estimates showed a strong correlation: r=0.77 (P-value<1x10<sup>-10</sup>; N=1,062,577) between LDSC and GNOVA, r=0.81 (P-value<1x10<sup>-10</sup>; N=59,289) between LDSC and HDL, and r=0.82 (P-value<1x10<sup>-10</sup>; N=59,289) between GNOVA and HDL. **Supplementary eFigure**
- 199 **4** shows the correlation of the three sets of estimates.
- Within the significant signals identified, we observed *i*) organ-specific associations, in which the MAE showed a genetic association with the DE originating from the respective organ system, and *ii*) cross-organ connections, in which the MAE and DE were primarily involved
- 203 from different organ systems. For example, two brain PSCs showed significant negative genetic
- 204 correlations with BIP from PGC (C512\_368 vs. BIP: -0.16±0.03; C1024\_114 vs. BIP: -
- 205 0.15±0.03). At a less stringent level, the brain MAEs were also genetically associated with DEs
- from other organ systems, including the positive correlation between C1024\_808 and obesity
- 207 (E4\_OBESITY:  $r_g = 0.17 \pm 0.13$ ). The cardiovascular BAG was positively correlated with several
- 208 DEs related to the cardiovascular system, including ischemic heart disease (I9\_IHD:
- 209  $r_g=0.26\pm0.03$ ), coronary heart disease (I9\_HEARTFAIL\_AND\_CHD:  $r_g=0.26\pm0.03$ ), angina
- 210 (I9\_ANGINA:  $r_g$ =0.25±0.03) and atrial fibrillation (I9\_AF:  $r_g$ =0.22±0.04). Likewise, the
- 211 pulmonary BAG was positively associated with multiple DEs related to the lung and respiratory
- system, including chronic obstructive pulmonary disease (COPD\_EARLY:  $r_g = 0.47 \pm 0.04$ ) and
- 213 various forms of asthma (ASTHMA\_NAS:  $r_q=0.43\pm0.04$ ). Cross-organ connections were
- established, such as between the pulmonary BAG and substance abuse
- 215 (KRA\_PSY\_SUBSTANCE\_EXMORE:  $r_g = 0.20 \pm 0.03$ ) and hypertension (I9\_HYPTENS:
- 216  $r_g=0.17\pm0.03$ ). Lastly, the metabolic BAG was largely linked to different forms of diabetes
- 217 (T2D:  $r_q = 0.40 \pm 0.04$ ).







The significant genetic correlation estimates  $(r_g)$  between 2024 MAEs and 525 DEs are depicted, considering two levels of corrections for multiple comparisons, considering the relatively smaller

sample sizes (<40,000) for brain MAEs compared to other organ MAEs (>100,000). Initially, we


- 223 reveal significant results shared between LDSC and GNOVA, employing Bonferroni correction
- 224 based solely on the number of MAEs (P-value<0.05/2024), uncovering 133 MAE-AE pairs.
- 225 Subsequently, a stricter correction based on both the number of MAEs and DEs is applied,
- 226 leading to 45 unique MAE-AE pairs marked as red squares; the numeric results are displayed
- 227 using results from LDSC. The genetic correlation for non-significant results was set to 0 for
- 228 visualization purposes. For the MAEs, readers can explore the BRIDGEPORT portal for a visual 229
- representation of the 2003 brain PSCs (e.g., C256 225: https://labs-
- 230 laboratory.com/bridgeport/MuSIC/C256\_225) and the other BAGs at the MEDICINE portal:
- 231 https://labs-laboratory.com/medicine.
- 232

#### 233 The brain, cardiovascular, and pulmonary MAEs are causally linked to DEs of multiple 234 organ systems

- 235 Employing five distinct two-sample Mendelian randomization estimators, we identified 39 (P-
- 236 value<0.05/633) and 15 (P-value<0.05/633/524) significant causal relationships, directed from
- 237 the MAE to DE, that withstood the Bonferroni correction at two different levels of rigors, as per
- 238 the inverse variance weighted (IVW) estimator and at least one of the other four estimators

#### 239 (Method 3c and Supplementary eTable 3).

- 240 Within the 15 significant causal relationships, the brain MAEs showed causal 241 connections with DEs from the brain, as well as DEs from other organ systems. For example, the
- brain PSC (C1024\_598) was causally linked to SCZ from PGC [P-value=9.89x10<sup>-8</sup>; OR (95% 242
- CI)=0.69 (0.59, 0.79); the number of IVs=7]. C1024\_684 was causally linked to Ventral hernia 243
- 244 from FinnGen [K11 VENTHER: P-value=1.09x10<sup>-7</sup>; OR (95% CI)=1.43 (1.25, 1.63); the
- 245 number of IVs=18]. The pulmonary BAG was causally linked to multiple DEs related to the
- 246 pulmonary system, including chronic obstructive pulmonary disease (COPD) [J10\_COPD: P-
- value=2.70x10<sup>-20</sup>; OR (95% CI)=1.77 (1.56, 2.00); the number of IVs=59] and asthma 247
- [ASTHMA\_PNEUMONIA: P-value=1.51x10<sup>-14</sup>; OR (95% CI)=1.67 (1.41, 1.96); the number of 248
- 249 IVs=59]. The cardiovascular BAG was causally linked to ischemic heart disease (IHD)
- 250 [ASTHMA PNEUMONIA: P-value= $1.09 \times 10^{-7}$ ; OR (95% CI)=1.64 (1.36, 1.96); the number of
- 251 IVs=37] (Fig. 3). The quality check of the significant signals is presented in Supplementary
- 252 eFolder 1. Supplementary eFile 6 presents the full set of results for the 521 FinnGen DEs and 4 253 PGC DEs.
- 254 255



256

#### 257 Figure 3: Causal relationship from the 2024 MAEs to the 525 DEs

The causal relationship from the 2024 MAEs to the 525 DEs revealed 39 significant MAE-DE

259 pairs, involving 633 MAEs as effective exposure variables (>8 instrumental variables before

harmonization) and 525 DEs as outcomes. Bonferroni correction was applied to identify

- potential significant causal signals based on *i*) the 633 MAEs (P-value< 0.05/633) and *ii*) the 633
- 262 MAEs and 525 DEs (P-value<0.05/633/524, denoted by the 15 red rectangles). Furthermore, we
- verified that the statistical significance attained for the IVW estimator was consistent and
   persisted across at least one of the other four Mendelian randomization estimators (Egger,
- persisted across at least one of the other four Mendelian randomization estimators (Egger,
   weighted median, simple mode, and weighted mode estimators). For visualization purposes, the
- 266 odds ratios for non-significant results were set to 1 and were left blank. For the MAEs, readers
- can explore the BRIDGEPORT portal for a visual representation of the 2003 brain PSCs (e.g.,
- 268 C32\_4: https://labs-laboratory.com/bridgeport/MuSIC/C32\_4) and the other BAGs at the
- 269 MEDICINE portal: <u>https://labs-laboratory.com/medicine</u>.
- 270

# The DEs involving Alzheimer's disease, diabetes, asthma, and hypertension exert causal effects on multi-organ MAEs


- 273 We then tested the inverse causality by employing the DEs as exposure and MAEs as outcome
- variables. We identified 47 (P-value<0.05/787) and 23 (P-value<0.05/787/214) significant causal
- relationships, directed from the DE to MAE, that survived the Bonferroni correction at two different levels of riggers (Mathed 20 and Sumplementary a Table 4)

### 276 different levels of rigors (**Method 3c** and **Supplementary eTable 4**).

- Within the 23 significant causal relationships (P-value<0.05/787/214), various forms of Alzheimer's disease were linked to the brain MAEs, including the brain BAG [G6 AD WIDE:
- 279 P-value= $3.03 \times 10^{-7}$ ; OR (95% CI)=1.10 (1.06, 1.13); the number of IVs=8] and metabolic BAG
- 280 [G6\_AD\_WIDE: P-value= $3.03 \times 10^{-7}$ ; OR (95% CI)=1.07 (1.04, 1.09); the number of IVs=8].
- Type 1 diabetes (E4\_DM1NASCOMP) was also causally linked to multiple brain PSCs. In
- addition, the cardiovascular BAG was causally linked to multiple heart diseases, including
- 283 hypertension [I9\_HYPTENS: P-value= $4.67 \times 10^{-31}$ ; OR (95% CI)=1.23 (1.19, 1.27); the number
- of IVs=110]. Several forms of asthma were causally linked to the pulmonary BAG, such as
- 285 allergic asthma [ALLERG\_ASTHMA: P-value=2.38x10<sup>-9</sup>; OR (95% CI)=1.09 (1.06, 1.13); the
- number of IVs=14]. Finally, obesity was also linked to the renal BAG [E4\_OBESITY: Pvalue= $2.74 \times 10^{-8}$ ; OP (05% CD=1.11 (1.07, 1.15); the number of IVa=101 (Fig. 4)
- 287 value= $2.74 \times 10^{-8}$ ; OR (95% CI)=1.11 (1.07, 1.15); the number of IVs=19] (**Fig. 4**).

#### 288 **Supplementary eFolder 2** presents the quality check results of the significant signals.

Supplementary eFile 7 presents the full set of results for the 521 FinnGen DEs and 4 PGC DEs.
 290




# Figure 4: Causal relationship from the 525 DEs to the 2024 MAEs

- The causal relationship from the 525 MAEs to the 2024 DEs revealed 47 significant DE-MAE
- 294 pairs, involving 214 DEs as effective exposure variables (>8 instrumental variables before
- harmonization) and 787 DEs as effective outcomes after quality checks. Bonferroni correction
- was applied to identify potential significant causal signals based on *i*) the 787 MAEs (P-
- 297 value<0.05/787) and *ii*) the 787 MAEs and 214 DEs (P-value<0.05/787/214, denoted by the 23
- red rectangles). Furthermore, we verified that the statistical significance attained for the IVW
- estimator was consistent and persisted across at least one of the other four Mendelian
- randomization estimators (Egger, weighted median, simple mode, and weighted mode
- 301 estimators). For visualization purposes, the odds ratios for non-significant results were set to 1
- and were left blank. For the MAEs, readers can explore the BRIDGEPORT portal for a visual
- 303 representation of the 2003 brain PSCs (e.g., C128\_13: <u>https://labs-</u>
- 304 <u>laboratory.com/bridgeport/MuSIC/C128\_13</u>) and the other BAGs at the MEDICINE portal:
- 305 <u>https://labs-laboratory.com/medicine</u>.
- 306

# 307 The polygenic risk scores of the 2024 MAEs

- 308 Using the PRS-CS<sup>45</sup> method, we derived the PRS of the 2024 MAEs. We found that the 1799
- 309 MAEs could significantly (P-value<0.05/2024) predict the phenotypic BAGs in the test/target
- data (split2 GWAS; detailed in **Method 3d**). Among these, 1791 brain MAEs resulted in
- 311 significant incremental  $R^2$  ranging from 0.11% to 10.70% to predict the phenotype of interest.
- 312 For example, the PSC (C1024\_593 for part of the cerebellum: <u>https://labs-</u>
- 313 <u>laboratory.com/bridgeport/MuSIC/C1024\_593</u>) showed an incremental of  $R^2$  10.70%. The renal
- BAG showed an incremental  $R^2$  of 5.92%, followed by the metabolic ( $R^2 = 5.67\%$ ) and
- 315 pulmonary BAG ( $R^2 = 3.86\%$ ) (Fig. 5a and (Supplementary eFile 8).
- We then applied the model to the entire UKBB population and performed a PRS-wide association study (PWAS), where the 2024 PRS-MAEs were linked to the 59 phenotypes that
- 318 were not initially used to compute the respective PRS, to avoid the circular bias<sup>46</sup>
- 319 (Supplementary eTable 5). Refer to Method 3d for details. We found 388 significant
- 320 associations (P-value<0.05/2024/59) between 7 PRS-MAEs and 41 phenotypes. Among these,
- 321 PSC C32\_1 showed the most associations (94%); the lifestyle factor for only fish intake (Field
- 322 ID: 16) was highly linked to multiple PRS-MAEs (16%). These results were expected because
- 323 the 59 phenotypes (e.g., cognitive and mental traits) are primarily linked to the brain, and
- 324 lifestyle factors were largely linked to multiple organ systems (Fig. 5b and Supplementary
- 325 **eFile 9**). All derived PRS will be returned to UKBB and made available to the community.
- 326
- 327



328 329

Figure 5: The polygenic risk score of the 2024 MAEs and PWAS

(a) The incremental  $R^2$  of the PRS derived by PRC-CS to predict the 2024 MAEs in the 330

- target/test data (i.e., the split2 GWAS). The y-axis indicates the proportions of phenotypic 331
- 332 variation that the PRS can significantly and additionally explain (i.e., incremental  $R^2$ ). The x-axis
- 333 lists the 8 organ systems. For the brain, we showed the PRS distribution of the significant results
- 334 from the 1791 brain PRS-MAEs; the other organ systems only have one PRS-MAE. (b) The
- 335 PWAS links the PRS-MAEs to the 59 additional phenotypes not used to compute the PRS-MAE
- 336 in the entire UKBB sample (P-value<0.05/2024/59).
- 337

#### 338 Discussion

339 This study expands previously established genetic atlases<sup>47,32</sup> by integrating AI-derived

endophenotypes via the 2024 MAEs within the multi-organ framework solely through GWAS

summary statistics. We demonstrate a promising avenue for advancing imaging genetic research
in two key aspects: *i*) integrating AI in imaging genetics and *ii*) exploring human aging and
disease through a multi-organ perspective.

344 By comprehensively depicting the genetic architecture of the 2024 MAEs, we showcased that AI endophenotypes supported the endophenotype hypothesis<sup>14,15</sup>, in which they showed 345 346 lower polygenicity and weaker negative selection effects than the disease diagnosis. First, it may 347 suggest that these intermediate phenotypes exist along the causal pathway, bridging the gap 348 between underlying genetics and "exo-phenotypes" like cognitive decline or disease diagnoses in 349 case/control studies, thus positioned closer to the core etiology and pathology. Secondly, many 350 of these 2024 MAEs originated from *in vivo* imaging methodologies like magnetic resonance 351 imaging (MRI). Consequently, they tend to exhibit reduced noise levels (i.e., a higher SNR) in 352 capturing disease-related effects and are less susceptible to biases, such as misclassification<sup>48</sup>. 353 case/control-covariate sample bias (e.g., studies matching comorbidities and other factors), and imbalanced case/control ratios, as evidenced in many GWASs in FinnGen. Especially for the 354 355 former, binary traits have a threshold for disease classification, leading to the dichotomization of 356 individuals into affected and unaffected categories. Thirdly, the 525 DEs often represent 357 complex diseases highly influenced by multiple genetic and environmental factors. Their 358 multifaceted nature, involving numerous genes with modest effects and environmental interactions<sup>49</sup>, can lead to a higher vulnerability to disease onset and clinical symptoms. 359 360 Consistent with this observation, we previously also found that one AI- and imaging-derived subtype of Alzheimer's disease<sup>50</sup> (AD1), but not the binary disease diagnosis, was genetically 361 correlated with brain age (GM- and WM-BAG)<sup>6</sup>. 362

363 We observed that brain MAEs were overall more polygenic than MAEs from other organ systems. Brain disorders are highly polygenic<sup>51</sup>. First, the brain is a highly complex organ with 364 365 intricate functions, and disorders affecting it are likely influenced by a larger number of genetic variants<sup>12,52</sup>. Second, many brain disorders are multifaceted, involving various aspects of brain 366 367 structure, function, and connectivity, which can be influenced by various genetic factors<sup>19</sup>. 368 Additionally, the brain regulates many physiological processes throughout the body, so 369 disruptions in its function can have widespread effects, potentially involving interactions with 370 multiple organ systems<sup>4</sup>. In addition, we found that most of the brain MAEs showed negative 371 selection signatures, including the 9 disease subtype DNEs and 4 brain BAGs; some of the brain 372 PSCs showed a positive S estimate (e.g., for the occipital lobe and subcortical structure, 373  $S=0.31\pm0.09$ : https://labs-laboratory.com/bridgeport/MuSIC/C32 18). The anticipated negative 374 selection signatures of biological age across multiple organs and disease subtypes are expected to 375 align with our prior findings, which revealed pervasive signatures of natural selection across a 376 range of complex human traits and functional genomic categories. This negative selection 377 signature prevents mutations with large deleterious effects from becoming frequent in the 378 population<sup>53</sup>. The positive selection signatures identified in certain brain PSCs may suggest that 379 positive selection may also play a role in shaping the genetic architecture of brain structural 380 networks.

The MUTATE atlas uncovered both established and previously undiscovered interactions
 concerning human systemic diseases within individual organs and across diverse organ systems.
 For example, within the cardiovascular system, the AI-derived MAE, cardiovascular BAG

showed both substantial genetic correlation (Fig. 2) and bi-directional causality (Fig. 3 and 4)

with multiple heart diseases, such as ischaemic heart disease<sup>54</sup>, heart failure<sup>55</sup>, and atrial 385 fibrillation<sup>56</sup>. Similarly, pulmonary BAG was also causally linked to multiple diseases related to 386 the lung and respiratory system, including COPD<sup>57</sup> and various forms of asthma<sup>58</sup>. Another 387 388 organ-specific connection was observed in neurologic diseases, encompassing conditions such as AD<sup>59</sup> and various mental disorders<sup>60</sup> linked to several MAEs associated with the brain, notably 389 several PSCs and WM-BAG. Cross-organ interplay was evidenced for several novel 390 391 connections. For instance, the brain PSCs exhibited causal connections to conditions extending 392 beyond the brain, such as ventral hernia and vein diseases, as well as systemic conditions, like 393 various forms of diabetes affecting the entire body. In contrast, AD appears to causally impact 394 multiple BAGs across various human organ systems, including the renal, immune, and metabolic 395 systems. It's widely recognized that AD, being a complex condition, triggers detrimental effects that influence several human organ systems<sup>59,61</sup>. Our previous study used imaging genetics to 396 investigate this multi-organ involvement along the disease continuum<sup>62</sup>. These results highlight 397 398 the clinical relevance and interpretation of these AI endophenotypes to quantify individual-level 399 organ health.

400 Emphasizing preventative strategies for specific chronic diseases is crucial to enhancing 401 overall multi-organ health. Our MAEs present opportunities as novel instruments for selecting 402 populations in clinical trials and facilitating therapeutic development. AD and various forms of 403 diabetes exemplify disease endpoints significantly impacting multiple human organ systems. AD 404 stands as the leading cause of dementia in older adults, presenting a persistent challenge in 405 medicine despite numerous pharmacotherapeutic clinical trials. These trials have included interventions, such as anti-amyloid drugs<sup>63,64</sup> and anti-tau drugs.<sup>65</sup>. The complexity and 406 multifaceted nature of the underlying neuropathological processes may account for the lack of 407 408 effective treatments. We call on the scientific community to embrace various mechanistic hypotheses to elucidate AD pathogenesis beyond amyloid and tau<sup>66,67</sup>. Likewise, the complexity 409 of diabetes, with its various contributing factors, renders prevention challenging<sup>68</sup>. Moreover, 410 411 diabetes often coexists with other chronic conditions affecting multiple organ systems, such as cardiovascular diseases, hypertension, and dyslipidemia<sup>69</sup>. Successful prevention strategies 412 413 require a holistic approach, encompassing lifestyle adjustments, education, healthcare access, 414 and societal considerations.

415

384

# 416 Limitation

417 This study presents several limitations. Primarily, our analyses were centered solely on GWAS 418 summary statistics derived from individuals of European ancestries. Future investigations should 419 extend these findings to diverse ethnic groups, particularly those that are underrepresented, to 420 ascertain broader applicability. This necessitates the research community's commitment to 421 embracing open science in AI and genetics. Secondly, the computational genomics statistical 422 methods utilized in this research rely on several underlying statistical assumptions, which could 423 potentially be violated and introduce bias. We mitigated bias by employing multiple 424 methodologies to compute heritability, genetic correlation, and causality to address this concern. 425 Additionally, we conducted thorough sensitivity checks, and the detailed results are provided 426 accordingly. Finally, these MAEs originated from a singular biomedical data modality, such as 427 MRI. Future investigations should explore utilizing AI across multi-omics data, such as integrating imaging and genetics<sup>70</sup>, to capture underlying disease effects more comprehensively. 428 429

# 430 **Outlook**

- 431 In summary, we introduced the MUTATE genetic atlas to comprehensively comprehend the
- 432 genetic architecture of AI endophenotypes and chronic diseases in multi-organ science. This
- 433 investigation underscores the potential of integrating AI into genetic research and supports a
- 434 comprehensive approach to investigating human diseases within a multi-organ paradigm.

# 435 STAR \* Methods

#### 436 Method 1: GWAS summary statistics

437 The present study solely utilized GWAS summary statistics; no individual-level data were used.

- 438 We downloaded the GWAS summary statistics from three web portals for the 2024 MAEs, 521
- 439 DEs from FinnGen, and 4 DEs from PGC, respectively.

# 440441 UKBB

442 UKBB is a population-based study of approximately 500,000 people recruited from the United

443 Kingdom between 2006 and 2010. The UKBB study has ethical approval, and the ethics

444 committee is detailed here: <u>https://www.ukbiobank.ac.uk/learn-more-about-uk-</u>

445 <u>biobank/governance/ethics-advisory-committee</u>.

446 The GWAS summary statistics for all the 2024 MAEs are publicly available at the

447 MEDICINE knowledge portal: <u>https://labs-laboratory.com/medicine</u>, which focuses on

448 disseminating scientific findings on imaging genetics and AI methods in multi-organ science.

- 449 Specifically, among the 2024 MAEs, 2003 PSCs at varying scales from C32 to C1024 were
- 450 structural covariance networks derived via the sopNMF method<sup>12</sup>. 9 DNEs<sup>1</sup> captured the
   451 neuroanatomical heterogeneity of four brain diseases (AD1-2, ASD1-3, LLD1-2, and SCZ1-2)
- neuroanatomical heterogeneity of four brain diseases (AD1-2, ASD1-3, LLD1-2, and SCZ1-2)
   using semi-supervised clustering or representation learning methods<sup>42,62,71,72</sup>. 12 multi-organ
- 453 BAGs (GM, WM, FC<sup>6</sup>, multimodal brain BAGs, cardiovascular BAG, eye BAG, hepatic BAG,
- 454 immune BAG, musculoskeletal BAG, metabolic BAG, pulmonary BAG, and renal BAG<sup>73</sup>) were
- 455 derived from various machine learning models to quantify the individual-level deviation from
- 456 typical brain aging due to various pathological effects. Detailed AI methodologies are presented
- 457 in **Method 2** for the MAEs, DNEs, and BAGs. All GWASs were performed within European  $\frac{74}{74}$
- 458 ancestries and using the GRCh37 human genome assembly; the GWAS model (PLINK<sup>74</sup> for 459 linear model and fastGWA<sup>75</sup> for linear mixed-effect model), sample sizes, and covariates
- 459 linear model and fastGWA<sup>75</sup> for linear mixed-effect model), sample sizes, and cova
   460 included are detailed in the original papers and also in **Supplementary eTable 1a**.

461 Harmonization of GWAS summary statistics across different models and consortia for 462 various software is crucial, such as aligning the effect allele and the direction of the effect size. 463 There's currently no established standard in the field for this process, although some advice has 464 been proposed<sup>76</sup>. Certain software harmonizes data based on the allele frequency of the effect allele, such as the *TwoSampleMR* package<sup>77</sup> for Mendelian randomization. In our UKBB MAE 465 466 GWAS summary data, we harmonized the effect allele as the alternative allele from PLINK and 467 A1 from fastGWA and provided its corresponding allele frequency. P-value, effect sizes (e.g., 468 BETA value and SE), and sample sizes are indicated too. The variant identifier is based on the rs

469 ID number, not the chromosome number and position number combination.

# 470

# 471 FinnGen

The FinnGen<sup>22</sup> study is a research project based in Finland that explores combined genetics and
health registry data to understand the underlying causes and mechanisms behind various disease
endpoints. It particularly emphasizes the genetic basis of diseases in the Finnish population
(>500,000) by conducting extensive GWAS and analyzing large-scale genomic data in
collaboration with multiple research institutions and organizations. FinnGen has generously

470 conaboration with multiple research institutions and organizations. I milden has generous
 477 made their GWAS results publicly available to the community for research purposes

- 4// made their GWAS results publicly available to the community for research purpos
- 478 (<u>https://www.finngen.fi/en/access\_results</u>).

479 The present study used the GWAS summary statistics version R9 released to the public 480 on May 11, 2022, after harmonization by the consortium. In the R9 release, FinnGen analyzed 481 2269 binary and 3 quantitative endpoints from 377,277 individuals and 20,175,454 variants. Regenie<sup>78</sup> was used to run the GWAS models, including sex, age, 10 PCs, and genotyping batch 482 483 as covariates. Genotype imputation was done with the population-specific SISu v4.0 reference 484 panel. In our analysis, we concentrated solely on binary DEs with case numbers exceeding 5000 485 to ensure adequate statistical power, given the highly imbalanced case/control ratios. As the 486 released data were based on the GRCh38 human genome assembly, we lifted the GWAS 487 summary statistics to the GRCh37 version for all genetic analyses. Supplementary eTable 1b details the included 521 DEs. More details can be found at the FinnGen website:

- details the included 521 DEs. More details can be found at the
  https://finngen.gitbook.io/documentation/v/r9/.
- The FinnGen team has systematically harmonized the GWAS summary data for the 521
   DEs involved. The alternative allele serves as the effect allele. The rsID number represents the
- 492 SNP; the chromosome number and position are also shared. The data includes P-values, effect
- 493 sizes, and allele frequencies for both the alternative and reference alleles.
- 494

### 495 **Psychiatric Genomics Consortium**

- 496  $PGC^{23}$  is an international coalition of researchers exploring the genetic underpinnings of
- 497 psychiatric disorders and beyond. This collaborative effort unites scientists globally to examine
- 498 and decipher extensive genomic datasets concerning various brain diseases. The primary goal of
- 499 PGC involves uncovering and comprehending the genetic elements that contribute to various
- 500 psychiatric disorders, such as schizophrenia, bipolar disorder, and major depressive disorder. We
- 501 downloaded GWAS summary statistics from the PGC website (https://pgc.unc.edu/for-
- 502 <u>researchers/download-results/</u>) and manually harmonized the data to our Mendelian
- 503 randomization analyses to replicate the FinnGen findings.
- 504 PGC did not harmonize the GWAS summary statistics; the available data information 505 depends on each study. Supplementary eTable 1c details the 4 DEs (AD, ADHD, bipolar 506 disorder, and schizophrenia) included after the data filtering procedure. First, we ensured that the 507 study population comprised individuals of European ancestry and, if necessary, lifted the data to 508 the human genome build assembly GRCh37. Secondly, we excluded two studies where the allele
- 509 frequency is unavailable because the *TwoSampleMR* package<sup>77</sup> requires this information to
- 510 harmonize the exposure and outcome data (e.g., flip the effect allele and effect size). Thirdly, we 511 confirmed that the GWAS summary statistics didn't overlap with UKBB data. Specifically, the
- 512 AD GWAS summary data<sup>79</sup> explicitly offered a version that excluded participants from UKBB.
- 512 AD GWAS summary data explicitly offered a version that excluded participants from OKE 513 In addition, the original dataset lacked a column for the rsID number. To deal with this, we
- 514 employed a mapping approach using the chromosome number and position to the dpSNP
- 515 database (version 150), which allowed us to obtain the corresponding rsID numbers. All 4 DE
- 516 GWAS summary data went through the same harmonization procedure as FinnGen (**Method 3c**)
- 517 518

# 519 Method 2: 2024 multi-organ AI endophenotypes

# 520 (a): The 2003 patterns of structural covariance of the brain

521 In our earlier study<sup>12</sup>, we utilized the sopNMF method on an extensive and varied brain imaging

- 522 MRI dataset (*N*=50,699, including data from UKBB) to generate the multi-scale brain PSCs. The
- 523 scale C ranges from 32 to 1024, progressively increasing by a factor of 2; 11 PSCs vanished
- 524 during models.

525 Biologically, the 2003 PSCs represent data-driven structural networks that co-vary across 526 brain regions and individuals in a coordinated fashion. Mathematically, the sopNMF method is a

- 527 stochastic approximation ("deep learning-analogy") constructed and extended based on
- 528 opNMF<sup>80,81</sup>. Consider an imaging dataset comprising n images, each containing d voxels. We
- represent the data as a matrix X, where each column corresponds to a flattened image: X =
- 530  $[x_1, x_2, ..., x_n], X \in \mathbb{R}^{d \times n}_{\geq 0}$ . The method factorizes X into two low-rank matrices  $W \in \mathbb{R}^{d \times r}_{\geq 0}$  and
- 531  $H \in \mathbb{R}_{\geq 0}^{r \times n}$ , subject to two important constraints: *i*) non-negativity and *ii*) column-wise 532 orthonormality. More mathematical details can be referred to the original references<sup>12,80,81</sup> and
- orthonormality. More mathematical details can be referred to the original references<sup>12,80,81</sup> and
   Supplementary eMethod 2a.
- 534

### 535 (b): The 9 dimensional neuroimaging endophenotypes of the brain

The nine DNEs captured the neuroanatomical heterogeneity of four brain diseases, including AD1-2 for  $AD^{62}$ , ASD1-3 for autism spectrum disorder<sup>42</sup>, LLD1-2 for late-life depression<sup>71</sup>, and SCZ1-2 for schizophrenia<sup>72</sup>. The underlying AI methodologies involved two different semisupervised clustering or representation learning algorithms: Surreal-GAN<sup>82</sup> and HYDRA<sup>83</sup>. Refer to a review for details of the semi-supervised learning<sup>84</sup>, which primarily seeks the so-called "*1to-k*" mapping patterns or transformations from reference domains (like healthy controls) to target domains (such as patients).

543 Surreal-GAN<sup>82</sup> was used to derive AD1-2<sup>62</sup>. It unravels the intrinsic heterogeneity 544 associated with diseases through a deep representation learning approach. The methodological 545 innovation, compared to its precentor Smile-GAN<sup>85</sup>, lies in how Surreal-GAN models disease 546 heterogeneity: it interprets it as a continuous dimensional representation, ensures a consistent 547 increase in disease severity within each dimension, and permits the simultaneous presence of 548 multiple dimensions within the same participant without exclusivity. More mathematical details 549 are presented in **Supplementary eMethod 2b**.

HYDRA<sup>83</sup> was employed to derive the other 7 DNEs. It utilizes a widely adopted 550 551 discriminative technique, namely support vector machines (SVM), to establish the "1-to-k" 552 mapping. The model extends multiple linear SVMs to the nonlinear domain by piecing them together. This approach serves the dual purpose of classification and clustering simultaneously. 553 554 Specifically, it creates a convex polytope by amalgamating hyperplanes derived from k linear 555 SVMs. This polytope separates the healthy control group from the k subpopulations within the 556 patient group. Conceptually, each face of this convex polytope can be likened to encoding each 557 subtype (categorical trait) or dimension (continuous trait), capturing distinctive disease effects 558 (Refer to Supplementary eMethod 2c).

559

### 560 (c): The 12 biological age gaps of nine human organ systems

561 The nine multi-organ BAGs (brain, cardiovascular, eye, hepatic, immune, musculoskeletal, metabolic, pulmonary, and renal) were derived from a previous study<sup>5</sup> that used AI to predict the 562 563 chronological age of healthy individuals without chronic medical conditions: AI-predicted age -564 chronological age. Using a 20-fold cross-validation procedure, we applied the model for each 565 organ system, employing a linear support vector machine. Before training each model iteration, 566 standardization was applied to measures (excluding categorical variables) within the training set. 567 The model was solved using sequential minimal optimization with a gap tolerance of 0.001. The 568 support vector regression settings were adjusted for optimization, adhering to established

569 principles in the field<sup>86</sup>.

570 Alongside the nine organ BAGs, we previously derived three multimodal brain BAGs

571 (GM, WM, and FC-IDP) using features from gray matter (GM), white matter (WM), and

572 functional connectivity (FC) in MRI scans<sup>6</sup>. We systematically compared four machine learning

573 models: SVR, LASSO regression, multilayer perceptron, and a five-layer neural network. We 574 employed nested cross-validation (CV) and included an independent test dataset<sup>87</sup> for a fair

574 employed nested cross-vandation (CV) and included an independent test dataset for a fair 575 comparison across different models and MRI modalities. This process involved an outer loop CV

575 comparison across different models and MRI modalities. This process involved an outer loop CV 576 with 100 repeated random splits: 80% for training and validation and 20% for testing. Within the

- 577 inner loop, a 10-fold CV was utilized for hyperparameter tuning. Furthermore, we reserved an
- 578 independent test dataset, which was kept unseen until the fine-tuning of the machine learning
- 579 models<sup>88</sup> (e.g., hyperparameters for SVR) was completed.
- 580

### 581 Method 3: Genetic analyses based on GWAS summary statistics

#### 582 (a): The genetic architecture of the 2024 MAEs and 525 DEs

Primarily, we used SBayesS<sup>39</sup> to estimate three sets of parameters that fully unveil the genetic 583 584 architecture of the 2024 MAEs and 525 DEs. SBayesS is an expanded approach capable of 585 estimating three essential parameters characterizing the genetic architecture of complex traits through a Bayesian mixed linear model<sup>89</sup>. This method only requires GWAS summary statistics 586 587 of the SNPs and LD information from a reference sample. These parameters include SNP-based heritability  $(h_{SNP}^2)$ , polygenicity ( $\pi$ ), and the relationship between minor allele frequency (MAF) 588 and effect size (S). We used the software pre-computed sparse LD correlation matrix derived 589 590 from the European ancestry by Zeng et al.<sup>39</sup>. More mathematical details can be found in the original paper from Zeng et al.<sup>39</sup>. We ran the *gctb* command<sup>89</sup> using the argument --sbayes S, and 591 left all other arguments by default. When applying SBayesS to the 2025 MAEs and 525 DEs 592 593 summary data, we found that 18 DEs failed to converge in the MCMC sampling, which may be 594 due to LD differences between FinnGen and UKBB samples (the latter was used as the LD 595 reference in SBayesS).

596 To benchmark different methods used in the field for SNP-based heritability estimates, 597 we also employed two other methods based on GWAS summary data: i)  $LDSC^{28}$  and ii) 598 SumHer<sup>33</sup>. LDSC relies on the principle that the correlation between SNP effect sizes and 599 linkage disequilibrium with neighboring SNPs can be used to estimate the proportion of 600 heritability explained by all SNPs using GWAS summary data. For LDSC, we used the 601 precomputed LD scores from the 1000 Genomes of European ancestry. All other parameters 602 were set to default in the software. After merging the GWAS summary statistics, we chose the 603 1000 Genomes reference panel for fair comparisons between the two studies and ensured that 604 **SNPs** were included in the analyses. For example. for most the DE 605 (RX\_PARACETAMOL\_NSAID), after merging with the reference panel LD, 1,171,361 606 remained. For the first MAE (C32\_1), 1,092,510 SNPs remained after the same merging 607 procedure. Furthermore, FinnGen didn't provide the original genotype data; they only shared the 608 LD information via the LDstore software but did not provide the allele information. 609 Consequently, we cannot generate in-sample LD scores using the LDSC software. Finally, a prior investigation<sup>90</sup> showcased the robustness of LDSC concerning the selection of LD 610 611 reference panels - multi-ethnic European, Finnish-only, non-Finnish European from 1000 612 Genomes Phase 3 data, and FINRISK Finnish reference panel – regarding heritability estimates 613 in four lipid traits within a Finnish population.

614 For SumHer, we used the BLD-LDAK model, as the software suggested. BLD-LDAK 615 stands for "Bayesian LD-adjusted Kinship," where LD-adjusted kinship refers to the calculation 616 of genetic relatedness between individuals using information about the correlation of alleles 617 between nearby SNPs (linkage disequilibrium). We used the software-provided tagging file, 618 generated from 2000 white British individuals, as a reference penal suggested by the software for 619 European ancestry groups. The HapMap3 data (https://www.broadinstitute.org/medical-and-620 population-genetics/hapmap-3) merged with the tested GWAS summary SNPs. Similarly, we 621 ensured sufficient SNPs remained after merging with the reference panel. All other parameters 622 were set to default. SumHer differs from LDSC in several ways: i) it models inflation 623 multiplicatively, whereas LDSC uses an additive approach; *ii*) it accounts for uneven LD patterns 624 and incorporates MAF on SNP effect; and iii) it utilizes a restricted maximum likelihood 625 solver rather than regression to estimate the  $h_{SNP}^2$ .

626

627 (b): Genetic correlation: We used three different methods to compute the MAE-DE pairwise 628 (N=2024x525=1,062,600) genetic correlations ( $r_g$ ): *i*) LDSC<sup>28</sup>, *ii*) GNOVA<sup>34</sup>, and *iii*) HDL<sup>38</sup>.

An earlier study<sup>92</sup> highlighted the significance of selecting an appropriate LD score 629 630 reference panel for genetic correlation estimates based on summary statistics. We generated the 631 same reference panel for LD scores across the three software for a fair comparison. For LDSC, 632 we used the precomputed LD scores from the 1000 Genomes of European ancestry provided by 633 the software. All other parameters were set by default. To employ GNOVA, we created the LD 634 scores utilizing the 1000 Genomes of European ancestry using the --save-ld argument within the 635 gnova.py script. For HDL, we used the provided scripts from HDL to generate the LD scores 636 using the same 1000 Genomes of European ancestry

637 (https://github.com/zhenin/HDL/wiki/Build-a-reference-panel).

638 Through our analysis, we found that the three packages have different levels of model 639 convergence rates, which is critical for future applications as these open-source packages claim 640 to advance genetic research. In particular, we found that LDSC (1,062,577/1,062,600) and 641 GNOVA (1,062,600/1,062,600) converged for most of the tested MAE-DE pairs, whereas HDL 642 failed a substantial proportion of the analyses, leading to only 59,291 out of the 1,062,600 MAE-643 DE pairs (refer to the raised issue: <u>https://github.com/zhenin/HDL/issues/30</u>). Therefore, in Fig. 644 2, we presented common significant results after Bonferroni corrections from the LDSC and 645 GNOVA, resulting in 133 and 45 significant signals corrected on *i*) the number of MAEs and *ii*) 646 the number of MAEs and DEs.

647

(c): Two-sample bidirectional Mendelian randomization: We employed a bidirectional, two sample Mendelian randomization using the *TwoSampleMR* package<sup>77</sup> to infer the causal
 relationships between the 2024 MAEs, 521 DEs from FinnGen, and 4 brain DEs from PGC.

651 The forward Mendelian randomization examined causality from the 2024 MAEs to the 652 525 DEs, while the inverse analysis investigated causality from the 525 DEs to the 2024 MAEs. The *TwoSampleMR* package<sup>77</sup> applied five different Mendelian randomization methods. We 653 654 presented the significant findings after the Bonferroni correction using the inverse variance 655 weighted (IVW) estimator, verifying that the correction remained significant in at least one of 656 the other four estimators (Egger, weighted median, simple mode, and weighted mode 657 estimators). For the significant signals, we performed several sensitivity analyses. First, a 658 heterogeneity test was performed to check for violating the IV assumptions. Horizontal

659 pleiotropy was estimated to navigate the violation of the IV's exclusivity assumption<sup>93</sup> using a

funnel plot, single-SNP Mendelian randomization approaches, and Mendelian randomization
Egger estimator. Moreover, the leave-one-out analysis excluded one instrument (SNP) at a time
and assessed the sensitivity of the results to individual SNP.

663 Critically, to enhance transparency and reproducibility, we followed a systematic procedure guided by the STROBE-MR Statement<sup>94</sup> in conducting all causality analyses. This 664 comprehensive approach encompassed the selection of exposure and outcome variables, 665 666 reporting full sets of statistics, and implementing sensitivity checks to identify potential 667 violations of underlying assumptions. First, we performed an unbiased quality check on the GWAS summary statistics. Notably, the absence of population overlapping bias<sup>29</sup> was 668 669 confirmed, given that FinnGen and UKBB participants largely represent European ancestry 670 populations without explicit overlap. For the four PGC DEs, we ensured that no UKBB 671 participants were included in the GWAS summary data. Furthermore, all GWAS summary 672 statistics were based on or lifted to GRCh37. Subsequently, we selected the effective exposure 673 variables by assessing the statistical power of the exposure GWAS summary statistics in terms of 674 instrumental variables (IVs), ensuring that the number of IVs exceeded 8 before harmonizing the 675 data. Crucially, the function "clump\_data" was applied to the exposure GWAS data, considering LD. The function "harmonise data" was then used to harmonize the GWAS summary statistics 676 677 of the exposure and outcome variables. This overall resulted in a smaller number (< 525 DEs or 678 2024 MAEs) of effective exposure/outcome variables in both forward and inverse Mendelian 679 randomization analyses, as certain GWAS summary data did not have enough IVs.

680

681 (d): PRS calculation: PRS calculation used the GWAS summary statistics from the split-sample sensitivity analysis from our previous studies<sup>12,6,4,1</sup>. We established PRS weights using split1 682 GWAS data as the base/training set, while the split2 GWAS summary statistics were used as the 683 684 target/testing data. Details of the quality control (QC) procedures are shown in our previous studies<sup>12,6,4,1</sup>. Following the QC procedures, PRS for the split2 group was computed using PRS-685 CS<sup>45</sup>. PRS-CS infers posterior SNP effect sizes under continuous shrinkage priors using GWAS 686 687 summary statistics and an LD reference panel (i.e., UKBB reference). To ascertain the most 688 suitable PRS, we conducted a linear regression encompassing different P-value thresholds 689 (0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5), while controlling for age, sex, intracranial volume (if 690 applicable), and the forty genetic principal components. The optimal P-value threshold for PRS-691 MAE was determined based on the highest incremental  $R^2$ .

692 After determining the optimal model, we applied the model to the entire UKBB sample 693 (~500k individuals). We then performed a PWAS to link the 2024 PRS-MAEs and 59 additional 694 phenotypes (Supplementary eTable 5) not used to compute the PRS-MAE to avoid the circular 695 bias<sup>46</sup>. The 59 phenotypes include cognitive scores (e.g., fluid intelligence score; Field ID: 696 20016, mental traits (e.g., fed-up feelings; Filed ID: 1960), and lifestyle factors (e.g., tea intake; 697 Filed ID: 1488). A linear regression was built considering the following covariates: sex (Field 698 ID: 31), smoking status (Field ID: 20116), weight (Field ID: 21002), standing height (Field ID: 699 50), waist circumstance (Field ID: 48), age at recruitment (Field ID: 21022), and first 40 genetic 700 principal components (Field ID: 22009).

701

702

# 703 Data Availability

- The results of the MUTATE atlas are disseminated at the MUTATE knowledge portal:
- 705 <u>https://labs-laboratory.com/mutate</u>. The GWAS summary statistics for the 2024 MAEs can be
- accessed publicly through the MEDICINE knowledge portal: <u>https://labs-</u>
- 707 <u>laboratory.com/medicine</u> and the BRIDGEPORT knowledge portal: <u>https://labs-</u>
- 708 <u>laboratory.com/bridgeport</u>. The GWAS summary statistics for the 521 DEs from FinnGen are
- publicly available at: <u>https://finngen.gitbook.io/documentation/v/r9/</u>. The GWAS summary
- 710 statistics for the 4 DEs from PGC are publicly available at: <u>https://pgc.unc.edu/for-</u>
- 711 <u>researchers/download-results/</u>. The study used only GWAS summary statistics rather than
- 712 individual-level data from the UK Biobank. However, the 2024 MAE GWAS data was initially
- derived from previous studies conducted under Application Numbers 35148 and 60698 from the
- UK Biobank.

# 715 Code Availability

- The software and resources used in this study are all publicly available:
- *GCTB*: <u>https://cnsgenomics.com/software/gctb/#Overview</u>, SNP-based heritability,
   polygenicity, and MAF/effect size ratio
- LDSC: <u>https://github.com/bulik/ldsc</u>, SNP-based heritability and genetic correlation
- SumHer: https://dougspeed.com/sumher/, SNP-based heritability
- GNOVA: <u>https://github.com/xtonyjiang/GNOVA</u>, genetic correlation
- *HDL*: <u>https://github.com/zhenin/HDL</u>, genetic correlation
- *TwoSampleMR*: <u>https://mrcieu.github.io/TwoSampleMR/index.html</u>, Mendelian
   randomization
- PRS-CS: <u>https://github.com/getian107/PRScs</u>, PRS
- 726

# 727 Competing Interests

728 None

729

# 730 Authors' contributions

- 731 Dr. Wen has full access to all the study data and is responsible for its integrity and accuracy.
- 732 Study concept and design: W.J
- 733 Acquisition, analysis, or interpretation of data: W.J
- 734 Drafting of the manuscript: W.J
- 735 Critical revision of the manuscript for important intellectual content: All authors
- 736 Statistical analysis: W.J

### 737 **References**

738	1.	Wen, J. <i>et al</i> .	Neuroimaging-	-AI Endophend	otypes of Brai	n Diseases in t	the General

- Population: Towards a Dimensional System of Vulnerability. 2023.08.16.23294179
- 740 Preprint at https://doi.org/10.1101/2023.08.16.23294179 (2023).
- 741 2. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
  742 schizophrenia. *Nature* 604, 502–508 (2022).
- 743 3. Kendler, K. & Neale, M. Endophenotype: a conceptual analysis. *Mol Psychiatry* 15, 789–
  744 797 (2010).
- 4. Wen, J. *et al.* The Genetic Architecture of Biological Age in Nine Human Organ Systems.

746 *medRxiv* 2023.06.08.23291168 (2023) doi:10.1101/2023.06.08.23291168.

5. Tian, Y. E. *et al.* Heterogeneous aging across multiple organ systems and prediction of

748 chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.

- Wen, J. *et al.* The genetic architecture of multimodal human brain age. *Nat Commun* 15, 2604 (2024).
- 751 7. Zhao, B. *et al.* Heart-brain connections: Phenotypic and genetic insights from magnetic
  752 resonance images. *Science* 380, abn6598 (2023).
- 8. McCracken, C. *et al.* Multi-organ imaging demonstrates the heart-brain-liver axis in UK
  Biobank participants. *Nat Commun* 13, 7839 (2022).
- Nie, C. *et al.* Distinct biological ages of organs and systems identified from a multi-omics
  study. *Cell Reports* 38, 110459 (2022).
- 10. Liu, Y. *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI using
  deep learning. *eLife* 10, e65554 (2021).

11. Oh, H. S.-H. *et al.* Organ aging signatures in the plasma proteome track health and disease.

760 *Nature* **624**, 164–172 (2023).

- 12. Wen, J. *et al.* Genomic loci influence patterns of structural covariance in the human brain.
- 762 *Proceedings of the National Academy of Sciences* **120**, e2300842120 (2023).
- 763 13. Hodson, R. Precision medicine. *Nature* **537**, S49–S49 (2016).
- 14. Gottesman, I. I. & Gould, T. D. The endophenotype concept in psychiatry: etymology and
- 765 strategic intentions. *Am J Psychiatry* **160**, 636–645 (2003).
- 15. Cannon, T. D. & Keller, M. C. Endophenotypes in the Genetic Analyses of Mental
- 767 Disorders. Annual Review of Clinical Psychology 2, 267–290 (2006).
- 768 16. Rajpurkar, P., Chen, E., Banerjee, O. & Topol, E. J. AI in health and medicine. *Nat Med* 28,
  769 31–38 (2022).
- 17. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
- 771 *Nature* **562**, 203–209 (2018).
- 18. Miller, K. L. *et al.* Multimodal population brain imaging in the UK Biobank prospective
- epidemiological study. *Nature Neuroscience* **19**, 1523–1536 (2016).
- 19. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK
  Biobank. *Nature* 562, 210–216 (2018).
- 20. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK
  Biobank. *Nature* 622, 329–338 (2023).
- Dhindsa, R. S. *et al.* Rare variant associations with plasma protein levels in the UK
  Biobank. *Nature* 622, 339–347 (2023).
- Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
  population. *Nature* 613, 508–518 (2023).

31

- 782 23. O'Donovan, M. C. What have we learned from the Psychiatric Genomics Consortium.
- 783 *World Psychiatry* **14**, 291–293 (2015).
- 24. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association
- studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005–D1012
- 786 (2019).
- 25. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. 2020.08.10.244293
  Preprint at https://doi.org/10.1101/2020.08.10.244293 (2020).
- 789 26. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex
- 790 traits. Nat Genet **51**, 1339–1348 (2019).
- 27. Shen, L. & Thompson, P. M. Brain Imaging Genomics: Integrated Analysis and Machine
  Learning. *Proceedings of the IEEE* 108, 125–162 (2020).
- 793 28. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from
- polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
- 795 29. Sanderson, E. et al. Mendelian randomization. Nat Rev Methods Primers 2, 1–21 (2022).
- 796 30. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
- instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*
- **44**, 512–525 (2015).
- 799 31. Open science. *Nature* **550**, 7–8 (2017).
- 800 32. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
- 801 *Nat Genet* **47**, 1236–1241 (2015).
- Speed, D. & Balding, D. J. SumHer better estimates the SNP heritability of complex traits
  from summary statistics. *Nat Genet* 51, 277–284 (2019).

- 804 34. Lu, O. *et al.* A Powerful Approach to Estimating Annotation-Stratified Genetic Covariance
- 805 via GWAS Summary Statistics. *The American Journal of Human Genetics* 101, 939–964
  806 (2017).
- 807 35. Smith, G. D. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology
- 808 contribute to understanding environmental determinants of disease? Int J Epidemiol 32, 1–
- 809 22 (2003).
- 810 36. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
  811 inference in epidemiological studies. *Hum Mol Genet* 23, R89-98 (2014).
- 812 37. Pierce, B. L. & Burgess, S. Efficient design for Mendelian randomization studies:
- subsample and 2-sample instrumental variable estimators. *Am J Epidemiol* 178, 1177–1184
  (2013).
- 815 38. Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic

816 correlations across human complex traits. *Nat Genet* **52**, 859–864 (2020).

- 817 39. Zeng, J. et al. Widespread signatures of natural selection across human complex traits and
- functional genomic categories. *Nat Commun* **12**, 1164 (2021).
- 40. Evans, L. M. *et al.* Comparison of methods that use whole genome data to estimate the
  heritability and genetic architecture of complex traits. *Nat Genet* 50, 737–745 (2018).
- 41. Ojavee, S. E., Kutalik, Z. & Robinson, M. R. Liability-scale heritability estimation for
- biobank studies of low-prevalence disease. *The American Journal of Human Genetics* 109,
  2009–2017 (2022).
- 42. Hwang, G. et al. Assessment of Neuroanatomical Endophenotypes of Autism Spectrum
- 825 Disorder and Association With Characteristics of Individuals With Schizophrenia and the
- 626 General Population. *JAMA Psychiatry* (2023) doi:10.1001/jamapsychiatry.2023.0409.

- 43. Makowski, C. *et al.* Discovery of genomic loci of the human cerebral cortex using
  genetically informed brain atlases. 8 (2022).
- 829 44. Matoba, N., Love, M. I. & Stein, J. L. Evaluating brain structure traits as endophenotypes
- using polygenicity and discoverability. *Human Brain Mapping* **43**, 329–340 (2022).
- 45. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via
- Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1776 (2019).
- 833 46. Kriegeskorte, N., Simmons, W. K., Bellgowan, P. S. F. & Baker, C. I. Circular analysis in
- systems neuroscience: the dangers of double dipping. *Nat. Neurosci.* **12**, 535–540 (2009).
- 835 47. Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human
- 836 phenotypes. *Nat Genet* **53**, 1415–1424 (2021).
- 48. Lee, S. H. *et al.* Genetic relationship between five psychiatric disorders estimated from
  genome-wide SNPs. *Nat Genet* 45, 984–994 (2013).
- 49. Hunter, D. J. Gene–environment interactions in human diseases. *Nat Rev Genet* 6, 287–298
  (2005).
- 841 50. Wen, J. et al. Genetic, clinical underpinnings of subtle early brain change along
- Alzheimer's dimensions. 2022.09.16.508329 Preprint at
- 843 https://doi.org/10.1101/2022.09.16.508329 (2022).
- 51. THE BRAINSTORM CONSORTIUM et al. Analysis of shared heritability in common
- disorders of the brain. *Science* **360**, eaap8757 (2018).
- Smith, S. M. *et al.* An expanded set of genome-wide association studies of brain imaging
  phenotypes in UK Biobank. *Nat Neurosci* 24, 737–745 (2021).
- 848 53. Walsh, B. & Lynch, M. Evolution and Selection of Quantitative Traits. (Oxford University
- 849 Press, 2018).

- 850 54. Plackett, B. A graphical guide to ischaemic heart disease. *Nature* **594**, S3–S3 (2021).
- 851 55. Peisker, F. *et al.* Mapping the cardiac vascular niche in heart failure. *Nat Commun* 13, 3027
  852 (2022).
- 853 56. Brundel, B. J. J. M. et al. Atrial fibrillation. Nat Rev Dis Primers 8, 1–23 (2022).
- 854 57. Barnes, P. J. et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers 1, 1–21
- 855 (2015).
- 856 58. Holgate, S. T. *et al.* Asthma. *Nat Rev Dis Primers* **1**, 1–22 (2015).
- 857 59. Ballard, C. et al. Alzheimer's disease. The Lancet **377**, 1019–1031 (2011).
- 858 60. Marshall, M. The hidden links between mental disorders. *Nature* **581**, 19–21 (2020).
- 859 61. Eiser, A. R. & Fulop, T. Alzheimer's Disease Is a Multi-Organ Disorder: It May Already
  860 Be Preventable. *J Alzheimers Dis* 91, 1277–1281 (2023).
- 861 62. Wen, J. et al. Genetic, clinical underpinnings of subtle early brain change along
- Alzheimer's dimensions. 2022.09.16.508329 Preprint at
- 863 https://doi.org/10.1101/2022.09.16.508329 (2022).
- 864 63. Guthrie, H. et al. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients
- 865 with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to
- 866 133 Weeks. J Alzheimers Dis **76**, 967–979 (2020).
- 64. Sevigny, J. *et al.* The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
- 868 *Nature* **537**, 50–56 (2016).
- 869 65. Congdon, E. E. & Sigurdsson, E. M. Tau-targeting therapies for Alzheimer disease. *Nat Rev*870 *Neurol* 14, 399–415 (2018).
- 871 66. Jack, C. R. *et al.* Tracking pathophysiological processes in Alzheimer's disease: an updated
  872 hypothetical model of dynamic biomarkers. *Lancet Neurol* 12, 207–216 (2013).

- 873 67. Frisoni, G. B. *et al.* The probabilistic model of Alzheimer disease: the amyloid hypothesis
  874 revised. *Nat Rev Neurosci* 23, 53–66 (2022).
- 875 68. Tomic, D., Shaw, J. E. & Magliano, D. J. The burden and risks of emerging complications
- of diabetes mellitus. *Nat Rev Endocrinol* **18**, 525–539 (2022).
- 877 69. DeFronzo, R. A. et al. Type 2 diabetes mellitus. Nat Rev Dis Primers 1, 1–22 (2015).
- 878 70. Yang, Z. et al. Gene-SGAN: discovering disease subtypes with imaging and genetic
- signatures via multi-view weakly-supervised deep clustering. *Nat Commun* **15**, 354 (2024).
- 880 71. Wen, J. et al. Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical
- 881 Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry
- 882 (2022) doi:10.1001/jamapsychiatry.2022.0020.
- 72. Chand, G. B. *et al.* Two distinct neuroanatomical subtypes of schizophrenia revealed using
  machine learning. *Brain* 143, 1027–1038 (2020).
- Wen, J. *et al.* The Genetic Architecture of Biological Age in Nine Human Organ Systems.
   *medRxiv* 2023.06.08.23291168 (2023) doi:10.1101/2023.06.08.23291168.
- 887 74. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
  888 Linkage Analyses. *Am J Hum Genet* 81, 559–575 (2007).
- Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-scale
  data. *Nat Genet* 51, 1749–1755 (2019).
- 891 76. MacArthur, J. A. L. *et al.* Workshop proceedings: GWAS summary statistics standards and
  892 sharing. *Cell Genomics* 1, (2021).
- 893 77. Hemani, G. et al. The MR-Base platform supports systematic causal inference across the
- human phenome. *eLife* **7**, e34408 (2018).

- 895 78. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
  896 binary traits. *Nat Genet* 53, 1097–1103 (2021).
- 897 79. Wightman, D. P. et al. A genome-wide association study with 1,126,563 individuals
- identifies new risk loci for Alzheimer's disease. *Nat Genet* **53**, 1276–1282 (2021).
- 899 80. Sotiras, A., Resnick, S. M. & Davatzikos, C. Finding imaging patterns of structural
- 900 covariance via Non-Negative Matrix Factorization. *NeuroImage* **108**, 1–16 (2015).
- 901 81. Zhirong Yang & Oja, E. Linear and Nonlinear Projective Nonnegative Matrix
- 902 Factorization. *IEEE Trans. Neural Netw.* **21**, 734–749 (2010).
- 903 82. Yang, Z., Wen, J. & Davatzikos, C. Surreal-GAN:Semi-Supervised Representation
- 204 Learning via GAN for uncovering heterogeneous disease-related imaging patterns. *ICLR*205 (2021).
- 906 83. Varol, E., Sotiras, A. & Davatzikos, C. HYDRA: Revealing heterogeneity of imaging and

907 genetic patterns through a multiple max-margin discriminative analysis framework.

- 908 *NeuroImage* **145**, 346–364 (2017).
- 909 84. Wen, J. et al. Subtyping Brain Diseases from Imaging Data. in Machine Learning for Brain
- 910 Disorders (ed. Colliot, O.) 491–510 (Springer US, New York, NY, 2023). doi:10.1007/978-
- 911 1-0716-3195-9\_16.
- 912 85. Yang, Z. *et al.* A deep learning framework identifies dimensional representations of
- Alzheimer's Disease from brain structure. *Nat Commun* **12**, 7065 (2021).
- 86. Chang, C.-C. & Lin, C.-J. LIBSVM: A library for support vector machines. ACM Trans.
- 915 Intell. Syst. Technol. 2, 1–27 (2011).

	916	87.	Samper-González, J. el	<i>t al.</i> Reproducible	evaluation of	classification	methods in
--	-----	-----	------------------------	---------------------------	---------------	----------------	------------

- 917 Alzheimer's disease: Framework and application to MRI and PET data. *NeuroImage* 183,
  918 504–521 (2018).
- 919 88. Wen, J. et al. Convolutional neural networks for classification of Alzheimer's disease:
- 920 Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).
- 921 89. Zeng, J. *et al.* Signatures of negative selection in the genetic architecture of human complex
  922 traits. *Nat Genet* 50, 746–753 (2018).
- 923 90. Hautakangas, H. LD Score regression for estimating and partitioning heritability of lipid
- 924 levels in the Finnish population. (University of Helsinki, Helsinki, 2018).
- 925 91. Speed, D., Holmes, J. & Balding, D. J. Evaluating and improving heritability models using
  926 summary statistics. *Nat Genet* 52, 458–462 (2020).
- 927 92. Zhang, Y. et al. Comparison of methods for estimating genetic correlation between
- 928 complex traits using GWAS summary statistics. *Brief Bioinform* **22**, bbaa442 (2021).
- 929 93. Bowden, J. et al. A framework for the investigation of pleiotropy in two-sample summary
- 930 data Mendelian randomization. *Stat Med* **36**, 1783–1802 (2017).
- 931 94. Skrivankova, V. W. et al. Strengthening the Reporting of Observational Studies in
- 932 Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA 326,
- 933 1614–1621 (2021).
- 934

# 935 Acknowledgment

- 936 We sincerely thank the UK Biobank (<u>https://www.ukbiobank.ac.uk/</u>), FinnGen
- 937 (https://www.finngen.fi/en), and PGC (https://pgc.unc.edu/) team for their invaluable
- 938 contribution to advancing clinical research in our field.